Abstract
Modulation of immune responses by the use of recombinant cytokines or cytokine genes is one of the strategies for cancer therapy. Although host immune responses are complex and many kinds of cells are involved, crucial steps for enhancing anti-tumor responses can be induced by a single or a few cytokines administered. However, cytokines may induce toxic reactions or produce no substantial effects, when the concentration is inappropriate. Administration of recombinant cytokine(s) has advantages in controlling the blood concentration and the biological activity that can be induced by the cytokine. Since cytokines are relatively unstable in vivo, cancer patients have to receive a large amount of the recombinant protein to maintain the required blood concentration for biological activity. Administration of the protein is thereby often toxic to the patients. In contrast, secretion of the cytokine from tumor or vehicle cells by gene transfer is another therapeutic maneuver. Previous preclinical studies have shown that cytokines which facilitate type 1 helper T (Th1) cells-mediated immune reactions but not Th2 cells-mediated reactions, when produced in tumors, are effective for anti-tumor responses. Several technical problems to express sufficient amounts of cytokines in appropriate target cells remain unresolved but the potential of cytokine gene therapy is being explored. Cytokine therapy trials also contributes to our present knowledge of how anti-tumor responses can be efectively produced in cancer patients, shedding the light on the generation of tumor-specific immunity in the patients.
Keywords: Cytokine therapy, cancer, recombinant, genes, antitumor response, immune, TH1, cytotoxic T lymphocytes, NK Cell, MART 1, Th2 effectir function, TNFA, IFN y production, vaccine, fas ligand, Natural killer, Major histocompatibility complex, Antigen presenting cell, Dendritic, CD40 ligand, Tumor necrosis factor, interleukin, Interferon, Granulocyte macrophage colony stimulating, Type 1 helper T, Lymphokine activated, Inducible protein 10, Monokine induced, Severe combined immunodeficient, Prostate specific antigen
Current Pharmaceutical Design
Title: Cytokine Therapy for Cancer
Volume: 6 Issue: 6
Author(s): M. Tagawa
Affiliation:
Keywords: Cytokine therapy, cancer, recombinant, genes, antitumor response, immune, TH1, cytotoxic T lymphocytes, NK Cell, MART 1, Th2 effectir function, TNFA, IFN y production, vaccine, fas ligand, Natural killer, Major histocompatibility complex, Antigen presenting cell, Dendritic, CD40 ligand, Tumor necrosis factor, interleukin, Interferon, Granulocyte macrophage colony stimulating, Type 1 helper T, Lymphokine activated, Inducible protein 10, Monokine induced, Severe combined immunodeficient, Prostate specific antigen
Abstract: Modulation of immune responses by the use of recombinant cytokines or cytokine genes is one of the strategies for cancer therapy. Although host immune responses are complex and many kinds of cells are involved, crucial steps for enhancing anti-tumor responses can be induced by a single or a few cytokines administered. However, cytokines may induce toxic reactions or produce no substantial effects, when the concentration is inappropriate. Administration of recombinant cytokine(s) has advantages in controlling the blood concentration and the biological activity that can be induced by the cytokine. Since cytokines are relatively unstable in vivo, cancer patients have to receive a large amount of the recombinant protein to maintain the required blood concentration for biological activity. Administration of the protein is thereby often toxic to the patients. In contrast, secretion of the cytokine from tumor or vehicle cells by gene transfer is another therapeutic maneuver. Previous preclinical studies have shown that cytokines which facilitate type 1 helper T (Th1) cells-mediated immune reactions but not Th2 cells-mediated reactions, when produced in tumors, are effective for anti-tumor responses. Several technical problems to express sufficient amounts of cytokines in appropriate target cells remain unresolved but the potential of cytokine gene therapy is being explored. Cytokine therapy trials also contributes to our present knowledge of how anti-tumor responses can be efectively produced in cancer patients, shedding the light on the generation of tumor-specific immunity in the patients.
Export Options
About this article
Cite this article as:
Tagawa M., Cytokine Therapy for Cancer, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400597
DOI https://dx.doi.org/10.2174/1381612003400597 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Anaphylaxis in Risky Populations
Current Pharmaceutical Design Cannabis: A Treasure Trove or Pandora's Box?
Mini-Reviews in Medicinal Chemistry Inflammation, Allergy and Asthma, Complex Immune Origin Diseases: Mechanisms and Therapeutic Agents
Recent Patents on Inflammation & Allergy Drug Discovery Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives
Current Pharmaceutical Biotechnology New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews State of the Art and Development of a Drug-Drug Interaction Large Scale Predictor Based on 3D Pharmacophoric Similarity
Current Drug Metabolism Multicomponent Synthesis of New Generation of Arylindolylmethyl-1,3- Indandiones Using bis Ionic Liquid [BDBDIm]Br
Letters in Organic Chemistry Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Synthesis of Biologically Active Catecholic Compounds via ortho-Selective Oxygenation of Phenolic Compounds Using Hypervalent Iodine(V) Reagents
Current Organic Synthesis Involvement of the Endogenous Opioid System in Cannabinoid Responses
Current Medicinal Chemistry - Central Nervous System Agents